The low-dose monoethylglycinexylidide test: Assessment of liver function with fewer side effects

Hepatology

Volumn 25, Issue 6, 1997, Pages 1323-1327

  Reichel, Christoph ^a   Nacke, Axel ^a   Sudhop, Thomas ^a   Wienkoop, Gernot ^a   Lüers, Claus ^a   Hahn, Corinna ^a   Pohl, Christoph ^b   Spengler, Ulrich ^a   Sauerbruch, Tilman ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Evangelisches Krankenhaus Kalk   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEETHYLLIDOCAINE; DRUG METABOLITE; LIDOCAINE;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE LIVER FUNCTION RELATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIDOCAINE; LIVER; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES;

EID: 0030979374     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250603     Document Type: Article

References (27)

1. Bargetzi MJ. Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450 III A4. Clin Pharmacol Ther 1989;46:521-527.
2. Thomson RD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 1973;78:499-508.
3. Oellerich M, Raude E, Burdelski M, Schulz M, Schmidt FW, Ringe B, Lamesch P, et al. Monoethylglycinexylidide formation kinetics. A novel approach to assessment of liver function. J Chem Clin Biochem 1987;25: 845-853.
4. Huang YS, Lee SD, Deng JF, Wu JC, Lu RH, Lin YF, Wang YJ, et al. Measuring lidocaine metabolite-monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993;19:140-147.
5. Oellerich M, Burdelski M, Ringe B, Lamesch P, Gubernatis G, Bunzendahl H, Pichlmayr R, et al. Lignocaine metabolite formation as a measure of pretransplant liver function. Lancet 1989;I:640-642.
6. Oellerich M, Burdelski M, Lautz HU, Rodeck B, Duewel J, Schulz M, Schmidt FW, et al. Assessment of pretransplant prognosis in patients with cirrhosis. Transplantation 1991;51:801-806.
7. Oellerich M, Burdelski M, Lautz HU, Binder L, Pichlmayr R. Predictors of one-year pretransplant survival in patients with cirrhosis. HEPATOLOGY 1991;14:1029-1034.
8. Testa R, Borzone S, Risso D, Bardellini E, Caglieris S, Campo N, Lantieri PB, et al. Formation kinetics of the lidocaine metabolite (MEGX) in patients with chronic active hepatitis and cirrhosis. Eur J Gastroenterol Hepatol 1992;5:845-851.
9. Shiffman ML, Luketic VA, Sanyal AJ, Duckworth PF, Purdum III PP, Contos MJ, Mills AS, et al. Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. HEPATOLOGY 1993; 19:933-940
10. Forte G, Rocco P, Costanzo A, Grimaldi E, Rossi R, Botiglieri ME, Biceglia O, et al. Monoethylglycinexylidide production as a measure in predicting hepatic histology. Ital J Gastroenterol 1995;26:159-162.
11. Meyer-Wyss B, Renner E, Luo H, Scholer A. Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests. J Hepatol 1993;19:133-139.
12. Reichen J. MEGX test in hepatology: the long-sought ultimate quantitative liver function test? J Hepatol 1993;19:4-7.
13. Reichel C, Wienkoop G, Nacke A, Spengler U. Monoethylglycinexylidide (MEGX)-Test. Dtsch Med Wschr 1995;120:179-183.
14. Bennet PN, Aarons LJ, Bending MR, Steiner JA, Rowland M. Pharmacokinetics of lidocaine and its deethylate metabolite: dose and time dependent studies in man. J Pharmacokin Biopharm 1982;3:265-281.
15. Conn HO. The trailmaking and number connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977;22: 541-550.
16. Melzack R. The McGill pain questionnaire: major properties and scoring methods. Pain 1975;1:277-299.
17. Chen Y, Potter JM, Ravenscroft DJ. A quick, sensitive high-performance liquid chromatography assay for monoethylglycinexylidide and lignocaine in serum/plasma using solid-phase extraction. Ther Drug Monit 1992;14: 317-321.
18. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokin Biopharm 1981;9:503-512.
19. Tanswell P, Koup J. TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program. Intern J Clin Pharm Ther Toxicol 1993;31: 514-520.
20. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
21. Oellerich M, Burdelski M, Ringe B, Wittekind CH, Lamesch P, Lautz HU, Gubernatis G, et al. Functional state of the donor liver and early outcome of transplantation. Transplant Proc 1991;23:1575-1578.
22. Schroeder TJ, Gremse DA, Mansour ME, Theuerling AW, Brunson ME, Ryckman FC, Suchy FJ, et al. Lidocaine metabolism as an index of liver function in hepatic transplant donors and recipients. Transplant Proc 1989;21:2299-2301.
23. Rademaker AW, Kellen J, Tam YK, Wyse DG. Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clin Pharmacol Ther 1986;40:71-80.
24. Gianelly R, von der Groeben JO, Spivack AP, Harrison DC. Effect of lidocaine on ventricular arrythmias in patients with coronary heart disease. N Engl J Med 1967;277:1215-1219.
25. Selden R, Sasahara AA. Central nervous system toxicity induced by lidocaine. JAMA 1967;202:142-143.
26. Thomson AH, Elliott HL, Kelman AW, Meredith PA, Whiting B. The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects. J Pharmacokin Biopharm 1987;15:101-115.
27. Drayer DE, Lorenzo DB, Werns S, Reidenberg MM. Plasma levels, protein binding, and elimination data of lidocaine and active metabolites in cardiac patients of various ages. Clin Pharmacol Ther 1983;34:14-22.